Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
Status:
Completed
Trial end date:
2019-01-03
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the duration of severe neutropenia (DSN) in
patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim
versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + monotheray plinabulin or
combination plinabulin/pegfilgrastim Severe neutropenia is an absolute neutrophil count (ANC)
<0.5 × 10^9/L. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the
chemotherapy in this study.